The Aspen Study
Study Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multinational Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis.
What is study about:
The purpose of this study is to evaluate the efficacy, safety, and tolerability of brensocatib as treatment for NCFBE in adults and adolescents. This study will also test the effect of brensocatib compared to a placebo.
Main Aim:
Is to help work out if Brensocatib is safe and effective to use in Children with Non-Cystic Fibrosis Bronchiectasis.
